RT Journal Article
SR Electronic
T1 ATP, an Agonist at the Rat P2Y4 Receptor, Is an Antagonist at the Human P2Y4 Receptor
JF Molecular Pharmacology
JO Mol Pharmacol
FD American Society for Pharmacology and Experimental Therapeutics
SP 926
OP 931
VO 57
IS 5
A1 Kennedy, Charles
A1 Qi, Ai-Dong
A1 Herold, Christopher L.
A1 Harden, T. Kendall
A1 Nicholas, Robert A.
YR 2000
UL http://molpharm.aspetjournals.org/content/57/5/926.abstract
AB The nucleotide selectivities of the human P2Y4(hP2Y4) and rat P2Y4 (rP2Y4) receptor stably expressed in 1321N1 human astrocytoma cells were determined by measuring increases in intracellular [Ca2+] under conditions that minimized metabolism, bioconversion, and endogenous nucleotide release. In cells expressing the hP2Y4 receptor, UTP, GTP, and ITP all increased intracellular [Ca2+] with a rank order of potency of UTP (0.55) > GTP (6.59) = ITP (7.38), (EC50, μM). ATP, CTP, xanthine 5′-triphosphate (XTP), and diadenosine 5′,5‴-P1,P4-tetraphosphate (Ap4A), all at 100 μM, were inactive at the hP2Y4 receptor. In cells expressing the rP2Y4receptor, all seven nucleotides increased intracellular [Ca2+] with similar maximal effects and a rank order of potency of UTP (0.20) > ATP (0.51) > Ap4A (1.24) ≈ ITP (1.82) ≈ GTP (2.28) > CTP (7.24) > XTP (22.9). Because ATP is inactive at the hP2Y4 receptor, we assessed whether ATP displayed antagonist activity. When coapplied, ATP shifted the concentration-response curve to UTP rightward in a concentration-dependent manner, with no change in the maximal response. A Schild plot derived from these data gave a pA2 value of 6.15 (KB = 708 nM) and a slope near unity. Additionally, CTP and Ap4A (each at 100 μM) inhibited the response to an EC50 concentration of UTP by ∼40 and ∼50%, respectively, whereas XTP had no effect. The inhibitory effects of ATP, CTP, and Ap4A were reversible on washout. Thus, ATP is a potent agonist at the rP2Y4receptor but is a competitive antagonist with moderate potency at the hP2Y4 receptor. The American Society for Pharmacology and Experimental Therapeutics